CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 112 enrolled
Drug / intervention
cilengitide +4 moredrug
Likely dose
Cilengitide (EMD 121974) IV in conjunction with temozolomide orally and radiation therapyAI-extracted
Key inclusion· 4
  • Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme)
  • No prior radiation therapy, chemotherapy, immunotherapy, or biologic agents for brain tumor; glucocorticoid therapy allowed
  • Recovered from immediate post-operative period and maintained on stable corticosteroid regimen (no increase for 5 days) prior to treatment start
  • Mini Mental State Exam score ≥15
Key exclusion· 6
  • Serious concurrent infection or medical illness jeopardizing safe treatment
  • Pregnant or breast-feeding
  • Concurrent therapy for tumor (chemotherapeutics or investigational agents)
  • Prior or concurrent malignancy, except curatively treated carcinoma-in-situ or basal cell carcinoma, or disease-free ≥5 years

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00085254
NCT00085254Phase 2Completed

A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)·interventional·Posted Jun 11, 2004·Updated Feb 25, 2016

In Brief

A Phase 2 clinical trial evaluating cilengitide, temozolomide, and 3 other interventions for Adult Giant Cell Glioblastoma and 2 related conditions. Completed, enrolled 112 participants across 8 sites.

Detailed Summary

Cilengitide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving cilengitide together with temozolomide and radiation therapy may kill more tumor cells. This randomized phase I/II trial is studying the side effects and best dose of cilengitide when given together with temozolomide and radiation therapy and to compare how well they work in treating patients with newly diagnosed glioblastoma multiforme

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 11, 2004
Enrollment StartApr 1, 2005
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 22.1 years ago

Interventions

cilengitidedrug

Given IV

temozolomidedrug

Given orally

radiation therapyradiation

Undergo radiotherapy

laboratory biomarker analysisother

Correlative studies

pharmacological studyother

Correlative studies